<p>在过去三个月中，6 位分析师对 Cormedix（纳斯达克：CRMD）发布了评级，提供了从看涨到看跌的多样化观点。</p>
<p>总结他们最近的评估，下面的表格展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>提供更深入的见解，分析师设定了 12 个月的价格目标，显示出平均目标为$13.83，最高预估为$15.00，最低预估为$13.00。当前平均价格较之前的平均目标$16.33 下降了 15.31%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770814843_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770814843_0.png"/></p>
<h2>解读分析师评级：详细分析</h2>
<p>通过对最近分析师行动的全面分析，描绘了 Cormedix 在金融专家中的认知。下面的总结概述了关键分析师、他们最近的评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>维持</td>
<td>买入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Brandon Folkes</td>
<td>HC Wainwright &amp; Co.</td>
<td>下调</td>
<td>买入</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超过市场</td>
<td>$13.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>下调</td>
<td>买入</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>维持</td>
<td>买入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>维持</td>
<td>买入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据不断变化的市场条件和公司表现频繁更新他们的建议。无论是'维持'、'上调'还是'下调'他们的立场，反映了他们对 Cormedix 相关最新发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 提供全面分析，分析师提供定性评估，从'超过市场'到'低于市场'。这些评级反映了对 Cormedix 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师在价格目标的调整中进行导航，提供对 Cormedix 未来价值的估计。比较当前和之前的目标提供了分析师不断变化的预期的见解。</li>
</ul>
<p>通过这些分析师评估与其他财务指标的结合，可以帮助全面理解 Cormedix 的市场地位。保持信息灵通，并通过我们的评级表做出数据驱动的决策。</p>
<p>随时了解 Cormedix 的分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>更好地了解 Cormedix</h2>
<p>Cormedix Inc 是一家生物制药公司，专注于开发和商业化针对危及生命的疾病和状况的治疗产品。该公司专注于在美国及其他关键市场商业化其产品 DefenCath。该集团目前在一个单一的细分市场运营，药品产品，位于一个地理位置，即美国。</p>
<h3>关键指标：Cormedix 的财务健康</h3>
<p><strong>市值：</strong> 与行业平均水平相比，公司的市值较小，面临独特的挑战。</p>
<p><strong>收入增长：</strong> Cormedix 在过去三个月中表现出积极的结果。截至 2025 年 9 月 30 日，该公司实现了约 <strong>810.22%</strong> 的强劲收入增长率。这表明公司的收入大幅增加。与竞争对手相比，该公司的增长率高于医疗保健行业的平均水平。</p>
<p><strong>净利润率：</strong> Cormedix 的净利润率超越行业基准，达到 <strong>104.11%</strong>。这表明其成本管理高效，财务健康状况良好。</p>
<p><strong>股本回报率（ROE）：</strong> Cormedix 的财务实力体现在其卓越的 ROE 上，超过行业平均水平。该公司的 ROE 达到 <strong>36.51%</strong>，展示了其对股本资本的高效利用和强劲的财务健康。</p>
<p><strong>资产回报率（ROA）：</strong> Cormedix 的 ROA 表现突出，超过行业平均水平。该公司的 ROA 达到 <strong>21.64%</strong>，展示了其资产的有效利用和强劲的财务表现。</p>
<p><strong>债务管理：</strong> Cormedix 的债务与股本比率显著高于行业平均水平，达到 <strong>0.4</strong>。这表明对借款资金的依赖较重，增加了财务杠杆的担忧。</p>
<h2>分析师评级是如何确定的？</h2>
<p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
<p>一些分析师还提供有助于预测收益、收入和增长估计等指标的预测，以进一步指导对特定股票的操作。需要记住的是，尽管股票和行业分析师是专家，但他们也是人，只能将自己的信念预测给交易者。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

CRMD

<p>在过去三个月中，六位分析师对 Cormedix（NASDAQ:CRMD）进行了评级，显示出从看涨到看跌的情绪混合。12 个月的平均目标价为 13.83 美元，低于 16.33 美元，最高为 15.00 美元，最低为 13.00 美元。分析师们调整了他们的评级，有些维持不变，有些则下调了目标价。Cormedix 显示出约 810.22% 的显著收入增长和 104.11% 的净利润率。然而，其债务与股本比率高于行业平均水平，表明其对借款资金的依赖</p>

<p>In the last three months, 6 analysts have published ratings on Cormedix (NASDAQ: CRMD), offering a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在过去三个月中，6 位分析师对 Cormedix（纳斯达克：CRMD）发布了评级，提供了从看涨到看跌的多样化观点。</p>
</div><p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<div class="lb-trans"><p>总结他们最近的评估，下面的表格展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $13.83, along with a high estimate of $15.00 and a low estimate of $13.00. Highlighting a 15.31% decrease, the current average has fallen from the previous average price target of $16.33.</p>
<div class="lb-trans"><p>提供更深入的见解，分析师设定了 12 个月的价格目标，显示出平均目标为$13.83，最高预估为$15.00，最低预估为$13.00。当前平均价格较之前的平均目标$16.33 下降了 15.31%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770814843_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770814843_0.png"/></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<div class="lb-trans"><h2>解读分析师评级：详细分析</h2>
</div><p>A clear picture of Cormedix's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过对最近分析师行动的全面分析，描绘了 Cormedix 在金融专家中的认知。下面的总结概述了关键分析师、他们最近的评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Brandon Folkes</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$13.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>维持</td>
<td>买入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Brandon Folkes</td>
<td>HC Wainwright &amp; Co.</td>
<td>下调</td>
<td>买入</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超过市场</td>
<td>$13.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>下调</td>
<td>买入</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>维持</td>
<td>买入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>维持</td>
<td>买入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cormedix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cormedix compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Cormedix's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据不断变化的市场条件和公司表现频繁更新他们的建议。无论是'维持'、'上调'还是'下调'他们的立场，反映了他们对 Cormedix 相关最新发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 提供全面分析，分析师提供定性评估，从'超过市场'到'低于市场'。这些评级反映了对 Cormedix 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师在价格目标的调整中进行导航，提供对 Cormedix 未来价值的估计。比较当前和之前的目标提供了分析师不断变化的预期的见解。</li>
</ul>
</div><p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Cormedix's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<div class="lb-trans"><p>通过这些分析师评估与其他财务指标的结合，可以帮助全面理解 Cormedix 的市场地位。保持信息灵通，并通过我们的评级表做出数据驱动的决策。</p>
</div><p>Stay up to date on Cormedix analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Cormedix 的分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>Get to Know Cormedix Better</h2>
<div class="lb-trans"><h2>更好地了解 Cormedix</h2>
</div><p>Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.</p>
<div class="lb-trans"><p>Cormedix Inc 是一家生物制药公司，专注于开发和商业化针对危及生命的疾病和状况的治疗产品。该公司专注于在美国及其他关键市场商业化其产品 DefenCath。该集团目前在一个单一的细分市场运营，药品产品，位于一个地理位置，即美国。</p>
</div><h3>Key Indicators: Cormedix's Financial Health</h3>
<div class="lb-trans"><h3>关键指标：Cormedix 的财务健康</h3>
</div><p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<div class="lb-trans"><p><strong>市值：</strong> 与行业平均水平相比，公司的市值较小，面临独特的挑战。</p>
</div><p><strong>Revenue Growth:</strong> Cormedix displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately <strong>810.22%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Cormedix 在过去三个月中表现出积极的结果。截至 2025 年 9 月 30 日，该公司实现了约 <strong>810.22%</strong> 的强劲收入增长率。这表明公司的收入大幅增加。与竞争对手相比，该公司的增长率高于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> Cormedix's net margin excels beyond industry benchmarks, reaching <strong>104.11%</strong>. This signifies efficient cost management and strong financial health.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Cormedix 的净利润率超越行业基准，达到 <strong>104.11%</strong>。这表明其成本管理高效，财务健康状况良好。</p>
</div><p><strong>Return on Equity (ROE):</strong> Cormedix's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>36.51%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Cormedix 的财务实力体现在其卓越的 ROE 上，超过行业平均水平。该公司的 ROE 达到 <strong>36.51%</strong>，展示了其对股本资本的高效利用和强劲的财务健康。</p>
</div><p><strong>Return on Assets (ROA):</strong> Cormedix's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>21.64%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Cormedix 的 ROA 表现突出，超过行业平均水平。该公司的 ROA 达到 <strong>21.64%</strong>，展示了其资产的有效利用和强劲的财务表现。</p>
</div><p><strong>Debt Management:</strong> Cormedix's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.4</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Cormedix 的债务与股本比率显著高于行业平均水平，达到 <strong>0.4</strong>。这表明对借款资金的依赖较重，增加了财务杠杆的担忧。</p>
</div><h2>How Are Analyst Ratings Determined?</h2>
<div class="lb-trans"><h2>分析师评级是如何确定的？</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
</div><p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<div class="lb-trans"><p>一些分析师还提供有助于预测收益、收入和增长估计等指标的预测，以进一步指导对特定股票的操作。需要记住的是，尽管股票和行业分析师是专家，但他们也是人，只能将自己的信念预测给交易者。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

分析师对 Cormedix 未来的预期